In recent years, an increasing proportion of syphilis cases in the United States have been diagnosed in men who have sex with men (MSM), often associated with high-risk sexual behavior and HIV coinfection. 6 In 2013, more than 16 000 of the total reported cases were primary and secondary syphilis, the most transmissible stages of infection, and three-quarters of these occurred in MSM. 6 The highest rates of primary and secondary syphilis are currently found in younger men (aged 20-29 years), a change since 2006, when those aged 35 to 59 years were most affected. Primary and secondary syphilis disproportionately affect black men, whose infection rate (27.9 per 100 000) is more than 5-fold higher than the rate among white men (5.4 per 100 000). 1 
Stages of Syphilis
Syphilis occurs in overlapping stages, classified according to symptoms and time since initial infection ( Table 1) . Appropriate staging is important for determining infectivity and treatment duration. A diagnosis of early syphilis (primary, secondary, and early latent syphilis) implies that T pallidum infection occurred within the previous year. 9 Late syphilis represents manifestations occurring more than 1 year and even decades after initial infection. Latent syphilis refers to T pallidum infection with reactive syphilis serologic findings but without clinical manifestations of disease. It includes both early latent (within 1 year of infection) and late latent (1 year or more after infection) syphilis.
Methods
One of us (M.E.C.) searched MEDLINE for English-language human treatment studies dating from January 1965 through July 2014. The initial search was limited to clinical trials, systematic reviews, and meta-analyses consisting of syphilis treatment studies. We excluded articles involving only diagnostic testing, screening, or prevention. Reference lists of identified articles were searched for additional relevant references (eFigure in the Supplement). Case reports and series were not included unless they were the only studies providing evidence for a specific treatment strategy. The American Heart Association classification of recommendations was used to grade the quality of evidence ( Table 2) . Grade A indicates data from many large randomized clinical trials (RCTs); grade B, data from fewer, smaller RCTs, careful analyses of nonrandomized studies, or observational registries; and grade C, expert consensus. 29 
Results

Treatment of Syphilis
The MEDLINE search for syphilis treatment identified 418 articles, of which 40 were included in this review. After reviewing the reference lists of these articles for additional relevant studies, we identified 102 articles for inclusion in our review, including RCTs, metaanalyses, and cohort studies. In total, the review included 11 randomized trials, and the evidence regarding penicillin and nonpenicillin regimens was reviewed from studies involving 11 102 patients ( Table 3 and Table 4 ).
Monitoring Syphilis Treatment Response
Both diagnosis and assessment of treatment response rely on serologic tests (Box). Treponemal tests detect antibodies to specific antigenic components of T pallidum, while nontreponemal tests detect antibodies to a nonspecific cardiolipin-cholesterol-lecithin reagin antigen produced by the host in response to syphilis infection. 39 Nontreponemal serologic tests such as the Venereal Disease Research Laboratory (VDRL) test or the rapid plasma reagin test are used to monitor treatment response because they usually correlate with disease activity. Different nontreponemal tests do not provide interchangeable measurements; for example, rapid plasma reagin titers are often higher than VDRL titers. In general, a 4-fold decline in nontreponemal titer (such as a decrease from 1:32 to 1:8) is needed to signify treatment response. There are limitations to relying on changes in serologic titers to monitor response to treatment. For example, a recent report demonstrated that 20% of patients with syphilis experienced at least a 1-dilution (2-fold) increase in nontreponemal titer within 14 days of treatment, suggesting that the actual baseline titer used to assess response is often underestimated. 40 Coinfection with HIV may also contribute to therapeutic uncertainty because HIV-infected patients may experience slower serologic response rates after apparently successful treatment. [41] [42] [43] [44] The Serofast State
The serofast state refers to a situation in which nontreponemal antibodies decline (often adequately) after treatment but fail to completely revert to nonreactive. 45 Persons with low pretreatment titers are also sometimes said to be serofast when there is minimal (Յ2-fold) or no change following treatment. The serofast state may represent a number of different phenomena, including persistent low-level T pallidum infection, variability of host antibody response to infection, or tissue injury due to nonsyphilitic inflammatory conditions. 46 A significant proportion of patients remain serofast after treatment (15%-41%), although rates depend on syphilis stage, pretreatment titer, and the time point at which response is assessed, all of which vary from study to study. 13, [47] [48] [49] [50] Available data suggest that re-treatment has a modest effect on the serofast state, with only 27% of such patients achieving serologic cure in 1 study. 46 
Efficacy of Parenteral Penicillin for Early Syphilis
Treatment of syphilis is based on stage of infection and on whether there is evidence of central nervous system involvement ( Figure) . Treponema pallidum remains extremely susceptible to penicillin, an antimicrobial agent targeting bacterial cell wall synthesis. During more than 60 years of use, there has never been a documented case of penicillin resistance. 51 The organism's slow dividing time (30-33 hours) requires the prolonged presence of killing (treponemicidal) concentrations of antimicrobial agents. Depot preparations achieve this goal and have thus become the mainstay of treatment based on decades of experience. 52, 53 Nonetheless, only limited clinical trial evidence of efficacy exists, and interpretation of data from available studies is complicated by heterogeneous definitions of syphilis stage, differences in treatment regimens, and nonstandard treatment outcome measurements (Table 3) . 10, [30] [31] [32] [33] [34] [35] Despite the limitations in published studies, the predominance of evidence, including more recent high-quality studies, supports the use of parenteral penicillin, and it remains the treatment of choice. The quality of evidence for penicillin and alternate therapies, graded according to the American Heart Association classification system, is shown in Table 2 .
For early syphilis, studies from the 1950s onward have focused on benzathine penicillin G (BPG) and demonstrate favorable cure rates and infrequent need for re-treatment. Historical estimates for the rate of treatment failure with a single dose of 2.4 mil-lion U of BPG are around 5%. 54 In 1956, Smith et al 34 reported BPG efficacy in early syphilis, finding that response rates with a single BPG injection were not different from multiple injections of procaine penicillin with aluminum monostearate (a long-acting formulation no longer widely available). At 2 years, 94.5% to 100% of all patients had a seronegative status, depending on stage. Similarly, Schroeter et al 36 showed no difference in outcomes with single-dose BPG compared with multiple-dose penicillin regimens (11.4% vs 10.7%-10.9% 2-year cumulative re-treatment rates). Some reports claim superiority with multiple doses rather than a single injection of BPG, 31, 32 but these studies have been criticized for lack of a control group or exclusion of reinfected patients based on serological response pattern (thus overestimating success, as some of those excluded patients may actually have had treatment failure). 55 A 1997 study by Rolfs et al 10 that included 541 patients remains the only large RCT for syphilis therapy from the 20th century. The study compared a single standard dose of 2.4 million U of intramuscular BPG with an "enhanced therapy" regimen (the addition of highdose oral amoxicillin/probenecid to BPG) and found no difference in outcome between the 2 groups. In that study, serologic failure was 
Penicillin in Late and Late Latent Syphilis
Minimal high-quality evidence exists to guide the therapy for late syphilis. It has been postulated that longer-duration penicillin therapy may be required for late syphilis because treponemes appear to divide more slowly during later stages of infection, but the validity of this concept has not been rigorously assessed. 7 Only limited data exist regarding late latent syphilis therapy. In 2005, Kiddugavu et al 25 published a secondary analysis of an RCT studying 818 patients (86%) who had presumptive late latent syphilis. Benzathine penicillin G, 2.4 million U intramuscularly, was given as a single dose or along with oral azithromycin. Response rates were modest (cure rates of 56%-63%). Smith et al published a small randomized pilot study in 2004 in which 7 of 10 HIV-infected patients treated with procaine penicillin had an appropriate decline in titers, although 2 subsequently relapsed and 3 remained in a serofast state. 37 Most participants in this study were not taking effective antiretroviral therapy (ART), and the majority were presumed to have late latent syphilis. Another study of HIV-infected patients not taking suppressive ART who had late latent syphilis (some with central nervous system involvement) showed that 3 weekly injections of BPG resulted in an appropriate serologic response in only 62%. 38 
Doxycycline
Several studies, mostly small and retrospective, indicate that doxycycline/tetracycline is effective treatment for early syphilis, with serologic response rates of 83% to 100%. [13] [14] [15] [16] [17] [18] [19] Most studies used oral doxycycline, 100 mg twice daily for 14 days, a regimen that has been shown to have 73% to 89% response rates in HIV-infected patients. 16, 17 Doxycycline is advantageous in that it has simultaneous activity against other sexually transmitted infections. However, the requirement for multiple days of treatment when using doxycycline introduces adherence concerns compared with the preferred single observed dosing with intramuscular BPG. As a result, doxycycline is considered an alternative to BPG in the treatment of syphilis.
Ceftriaxone
Several small studies of intramuscular ceftriaxone for early syphilis have shown efficacy comparable with penicillin G. 16,20-23 Most of these trials used parenteral once-daily doses of 1 to 2 g for 10 to 15 days with serologic response rates of 65% to 100%. The lowest response rates were seen in HIV-infected patients, particularly among patients with incomplete HIV suppression. Treatment failure was most often noted in HIV-infected patients with latent syphilis. 37, 38 Ceftriaxone treatment of syphilis requires multiple daily parenteral doses and is both more cumbersome and more expensive than single-dose BPG but has the advantage of treating other coexisting sexually transmitted infections and may be useful in patients with penicillin allergy. 57 Use of cephalosporins in patients with penicillin allergy is discussed below.
Azithromycin
Randomized clinical trials have shown that oral azithromycin (as a single 1-to 2-g dose) is effective in the treatment of early syphilis, with much of the data derived from studies done in Africa. 11, 12, 24 The emergence of azithromycin resistance mutations in T pallidum with resultant treatment failure has limited its usefulness in many regions of the United States. 56, [58] [59] [60] [61] [62] In a study of 141 T pallidum samples collected from 11 US clinics between 2007 and 2009, the 23s rRNA A2058G point mutation (associated with macrolide resistance/ treatment failure) was found in 53% of specimens. 61 Azithromycin has also been associated with a 5-fold greater risk of gastrointesti- The Jarisch-Herxheimer reaction is a significant adverse event that can occur with any antibiotic treatment for syphilis but is most common after penicillin. This reaction manifests with systemic symptoms including fever, rash, malaise, headache, and myalgias, typi-cally occurring within 24 hours of treatment of early syphilis. It is seen in 10% to 35% of patients and is usually self-limited. 63 The reaction is thought to result from release of lipoproteins, cytokines, and immune complexes from killed organisms. 63, 64 Penicillin Allergy and Penicillin Desensitization
Given the availability of nonpenicillin options for the treatment of syphilis, the need for penicillin desensitization approaches seems limited, and it is not well studied. 65 However, in some settings, penicillin is clearly the treatment of choice and desensitization is probably the preferred option in the following situations: (1) neurosyphilis in persons with a history of severe immediate hypersensitivity reaction to penicillin; (2) tertiary syphilis in all penicillin-allergic patients; (3) any stage of syphilis in penicillin-allergic pregnant women; and (4) congenital syphilis in penicillin-allergic infants. 7 Special Circumstances: Neurosyphilis, HIV-Infected Persons, and Pregnant Women Neurosyphilis Successful neurosyphilis treatment requires the presence of adequate, prolonged cerebrospinal fluid (CSF) concentrations of a treponemicidal antimicrobial ( Table 5 ). Benzathine penicillin G should not be used because it does not reliably achieve sufficient concentrations in CSF. Intravenous administration of aqueous crystalline penicillin G achieves adequate CSF levels and is the treatment of choice for neurosyphilis. 69 Procaine penicillin injections also achieve treponemicidal levels in CSF, and there is evidence of clinical im-
Box. Serologic Tests for Syphilis
Treponemal tests: detect antibodies to specific antigenic components of Treponema pallidum provement in some studies, but the regimen is often difficult to complete because of the need for multiple intramuscular injections that can be painful and the requirement for adherence to oral probenecid 4 times daily. 70, 71 Treatment of neurosyphilis in patients with significant penicillin allergy is challenging, and penicillin desensitization is probably the best option. Ceftriaxone (2 g/d intramuscularly or intravenously for 10-14 days) is an alternative, but evidence of its efficacy is limited. [72] [73] [74] Risk of cross-reactivity between penicillin and ceftriaxone is negligible, but skin testing for β-lactam allergy and desensitization can be done if needed. 7, 57 
HIV Coinfection
Syphilis and HIV infection are strongly linked with one another. Most of the recent increase in syphilis cases in the United States has occurred in MSM, and rates of HIV coinfection as high as 50% to 70% have been reported among MSM diagnosed as having primary and secondary syphilis. 75 There are few studies comparing syphilis treatment of HIVcoinfected patients with HIV-uninfected controls. 76 Patients with HIV infection may be at increased risk of serologic failure following treatment, although this is controversial. 41, 43 Some studies comparing serologic response rates between HIV-infected and uninfected persons show no difference in treatment success rates. 10, 77 Other studies attribute the perceived increased risk of treatment failure to a slower decline in titer in HIV-infected individuals. 42 Lower CD4 cell counts are associated with delayed treatment response and increased risk of serologic failure among HIV-infected patients. 41,78 Data from the pre-ART era suggest a shorter latency period before progression to neurosyphilis and an increased risk of progression to neurosyphilis despite adequate treatment for early syphilis. [79] [80] [81] Based on these observations, some authorities recommend a longer duration of penicillin for early syphilis in HIV-infected persons (7.2 million U of BPG given as 3 weekly 2.4 million-U doses). 82 A recent retrospective study of patients with primary and secondary syphilis found a nonsignificant increase in serologic response rates in HIV-infected patients who received 3 weekly doses of penicillin compared with those treated with a single dose of BPG (serologic cure in 88% with a single dose vs 97% with 3 doses; P = .18); however, another study from 2013 demonstrated no difference in BPG treatment outcome between single-dose treatment and multiple-dose (3 weekly injections) treatment in HIV-infected patients with early syphilis. 28, 78 Effective ART appears to reduce the likelihood of serologic failure as well as progression to neurosyphilis. 83, 84 While HIV infection appears to affect syphilis outcomes, syphilis also appears to affect the course of HIV infection. Increased HIV replication and reduced CD4 cell counts have been reported among HIV-infected patients with syphilis, highlighting the importance of appropriate treatment for both infections. [85] [86] [87] 
HIV Infection and Neurosyphilis
Reports of increased risk of neurosyphilis emerged soon after recognition of the HIV epidemic. 80, 81, 88, 89 As with all patients, successful treatment of neurosyphilis in HIV-infected persons requires sustained treponemicidal CSF penicillin concentrations. Some studies suggest that as many as 60% of HIV-infected patients may have failure of currently recommended neurosyphilis therapy with intravenous penicillin G. 81, 90, 91 Although penicillin is the preferred treatment for neurosyphilis, ceftriaxone, 1 to 2 g/d intravenously for 10 days, is thought to be an effective alternative in HIV-infected patients with neurosyphilis based on data from small observational studies. 37, 38, 92 One prospective study demonstrated that HIVinfected patients with low CD4 cell counts (<200/mL) were less likely to clear CSF-VDRL titers after treatment, illustrating the need for immune recovery facilitated by effective ART as part of optimal management. 93
Pregnant Women
Most cases of congenital syphilis result from transmission of T pallidum to the fetus during early syphilis, while most adverse pregnancy outcomes occur in women treated for syphilis in the third trimester, demonstrating the importance of timely syphilis screening and treatment in pregnancy. 94, 95 Observational studies of syphilis in pregnant women suggest that standard treatment based on stage of syphilis at diagnosis is sufficient. [96] [97] [98] [99] A Cochrane review published in 2010 found no syphilis treatment studies that met predetermined criteria for treatment group comparisons nor any that used randomly allocated groups of pregnant women. 100, 101 Risks associated with the Jarisch-Herxheimer reaction in pregnant women may be significant, including induction of early labor or fetal distress. Pregnant women should be warned about this potential outcome prior to treatment, but therapy should not be delayed or withheld. Alternatives to penicillin are not recommended because of potential fetal toxicity (doxycycline) or failure of treatment to cross the placenta (azithromycin). There is limited evidence suggesting that parenteral ceftriaxone is effective, but no controlled trials have been performed. 7, 101 
Discussion
Based on this review of the available literature, the preferred regimen for early syphilis, including primary, secondary, and early latent infection, is 2.4 million U of BPG in a single intramuscular injec- Treatment response should be assessed by repeat measurements of nontreponemal serologic titers at 6 and 12 months following treatment of primary and secondary syphilis and at 6, 12, and 24 months for late and latent syphilis. Patients who are in a serofast state do not appear to benefit substantially from re-treatment. Doxycycline and ceftriaxone are also effective treatments for early syphilis when penicillin cannot be used, and reasonable evidence exists to support the use of either as alternatives to penicillin. Because of the potential for resistance, azithromycin should not be used to treat patients in the United States except when other agents are not available. Careful follow-up is essential. Treatment of neurosyphilis should be aqueous crystalline penicillin G, 18 million to 24 million U/d via continuous infusion or divided into 6 daily doses for 10 to 14 days. Unfortunately, the data supporting this treatment regimen are modest and largely based on achievement of adequate treponemicidal CSF concentrations rather than demonstrated clinical efficacy. Individuals with HIV infection should be treated similarly to uninfected patients based on the available evidence and because the preponderance of data on syphilis treatment in HIV-infected persons were compiled in the era prior to the widespread availability of effective ART (which likely improves syphilis treatment responses). Although evidence is limited in pregnant women, the preferred treatment is penicillin, and pregnant women known to have penicillin allergy should be desensitized. 7 Our recommendations align with those of the Centers for Diseases Control and Prevention (CDC). Although a few large RCTs support the current CDC recommendations, they are primarily based on results from early, uncontrolled studies and on decades of clinical experience. The best data exist for early syphilis because it encompasses the majority of diagnosed cases. In contrast, evidence in support of treatment recommendations for late and late latent syphilis is quite limited, as is also true for neurosyphilis, for HIV-infected persons, and for pregnant women. The CDC's guidelines for treating syphilis in the setting of HIV infection are largely based on data from a 1997 RCT (done before the era of effective ART) that showed that HIV-infected patients respond comparably with HIV-uninfected persons. 10 However, only 69 HIV-infected persons in this study completed 6 months of follow-up and the only clinical failure occurred in an HIV-infected patient. Given the increasing rate of syphilis in the MSM population, there is a need for additional highquality studies.
Conclusions
After declining to historic lows at the turn of the 21st century, the incidence of syphilis has progressively increased in the United States, particularly in MSM. Penicillin remains the treatment of choice for all stages of syphilis, with different regimens suggested based on stage. Rigorous data from clinical trials to support the recommended regimens are generally lacking, and most existing data are limited by the lack of a gold standard to assess cure. Furthermore, the absence of homogeneous diagnostic definitions and outcome measurements among the available studies limits comparisons. 102 Larger, high-quality studies would be beneficial, especially in the disproportionately affected HIV-infected population, but seem unlikely to be carried out. Current recommendations are largely driven by clinical experience and expert opinion because available data are limited and sometimes conflicting. The accumulated clinical experience suggests that the current guidelines are largely successful. With the preponderance of available clinical data supporting penicillin as the preferred treatment option, the use of benzathine penicillin G offers a convenient, directly observed regimen that combines ease of administration with demonstrated antitreponemal activity. Penicillin will likely remain the cornerstone of syphilis treatment for years to come.
